跳至主要内容
临床试验/IRCT2015081810181N6
IRCT2015081810181N6已完成2 期

Assessment of the effect of oral hesperidin supplement on glycemic and lipidemic risk factors, visceral adiposity index, serum levels of oxidant, inflammatory and oxidative DNA damage markers in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trial

Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences0 个研究点目标入组 64 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 years 至 60 years(—)
性别
All

入选标准

  • inclusion criteria:
  • having type 2 diabetes for at least 3 years, oral hypoglycemic medications consumption and having informed written consent
  • exclusion criteria:
  • any change in type or dose of drug during the last 3 months, BMI ranges above 30, having history of other endocrine disorders, heart, hepatic and kidney diseases,using steroid drugs or hormones, having vitamin or mineral supplementation during previous 3 month

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences

相似试验